1251. 5-year outcomes of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as initial treatment of HIV-1 in adults with high baseline HIV-1 RNA and/or low CD4 count in two Phase 3 randomized clinical trials

BACKGROUND: People with HIV (PWH) who are initiated on guidelines-recommended first-line INSTI-based antiretroviral therapy routinely achieve rapid virologic suppression; however, those with a high baseline (BL) HIV-1 RNA and/or low CD4 count may be more challenging to manage in the short- and long-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramgopal, Moti, Wurapa, Anson, Baumgarten, Axel, Berhe, Mezgebe, Pozniak, Anton, Orkin, Chloe, Tiraboschi, Juan Manuel, Hagins, Debbie P, Huang, Hailin, Andreatta, Kristin, Unger, Nathan, Hindman, Jason, Martin, Hal, Baeten, Jared, Osiyemi, Olayemi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752362/
http://dx.doi.org/10.1093/ofid/ofac492.1082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752362/
http://dx.doi.org/10.1093/ofid/ofac492.1082

Ejemplares similares